Neurological complications post - COVID-19 infection
DOI:
https://doi.org/10.52692/1857-0011.2024.3-80.10Keywords:
Covid-19, neurological complications, headache, Guillain-Barre syndrome, cognitive disordersAbstract
The Sars-CoV-2 virus is from the coronavirus group with an affinity for affecting several systems, such as respiratory, cardiovascular, renal, gastrointestinal. A special role belongs to the nervous system, this infection involving the central nervous system (CNS) and the peripheral nervous system (PNS). The main viral transmission routes are the peripheral, hematogenous and lymphatic routes. Angiotensin convertase 2 (ACE2) has an essential role in the pathogenesis of Covid-19, underlies the inflammatory mechanisms and the so-called “cytokine storms”, influencing the development of coagulopathies and subsequent complications, with viral invasion of brain tissue due to crossing the blood-brain barrier. In the article, we analysed the main routes of viral invasion, as well as the neurological complications developed,involving both the central and peripheral nervous systems.
References
E. Beghi et al., “Approaches to Understanding COVID-19 and its Neurological Associations,” Ann Neurol, vol. 89, no. 6, 2021, doi: 10.1002/ana.26076.
R. Helbok et al., “NeuroCOVID: it’s time to join forces globally,” 2020. doi: 10.1016/S1474-4422(20)30322-7.
K. Keyhanian, R. P. Umeton, B. Mohit, V. Davoudi, F. Hajighasemi, and M. Ghasemi, “SARS-CoV-2 and nervous system: From pathogenesis to clinical manifestation,” 2021. doi: 10.1016/j. jneuroim.2020.577436.
S. Singh, N. Meher, A. Mohammed, M. K. A. A. Razab, L. V. K. S. Bhaskar, and N. M. Nawi, “Neurological infection and complications of SARS-CoV-2: A review,” Feb. 03, 2023, Ediciones Doyma, S.L. doi: 10.1097/MD.0000000000030284.
Y. Leven and J. Bösel, “Neurological manifestations of COVID-19 – an approach to categories of pathology,” Neurol Res Pract, vol. 3, no. 1, 2021, doi: 10.1186/ s42466-021-00138-9.
A. Yassin et al., “Neurological manifestations and complications of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis,” BMC Neurol, vol. 21, no. 1, 2021, doi: 10.1186/ s12883-021-02161-4.
G. Nepal et al., “Neurological manifestations of COVID-19: A systematic review,” Crit Care, vol. 24, no. 1, 2020, doi: 10.1186/s13054-020-03121-z.
S. H. Y. Chou et al., “Global Incidence of Neurological Manifestations among Patients Hospitalized with COVID-19 - A Report for the GCS-NeuroCOVID Consortium and the ENERGY Consortium,” JAMA Netw Open, 2021, doi: 10.1001/ jamanetworkopen.2021.12131.
E. Beghi et al., “Short- and long-term outcome and predictors in an international cohort of patients with neuro-COVID-19,” Eur J Neurol, vol. 29, no. 6, 2022, doi: 10.1111/ene.15293.
C. Fernández-de-las-Peñas et al., “The presence of headache at onset in SARS-CoV-2 infection is associated with long-term post-COVID headache and fatigue: A case-control study,” Cephalalgia, vol. 41, no. 13, pp. 1332–1341, Nov. 2021, doi: 10.1177/03331024211020404.
B. F. Guedes, “NeuroCOVID-19: a critical review,” May 01, 2022, Associacao Arquivos de Neuro- Psiquiatria. doi: 10.1590/0004-282X-ANP- 2022-S136.
J. González-Menacho, M. Villas-Roca, H. Castañé, J. Joven, J. Camps, and S. Iftimie, “Can COVID-19 vaccines relieve severe tension-type headache and migraine?,” Med Hypotheses, vol. 161, Apr. 2022, doi: 10.1016/j.mehy.2022.110812.
E. Cebotari, O. Grosu, S. Odobescu, L. Rotaru, G. Corcea, and I. Moldovanu, “Medication overuse in patients with headache during the COVID-19 pandemic,” vol. 64, no. September, p. 80009, 2021.
O. Grosu, “Consumul medicamentos la pacienții cu cefalee în perioada post COVID,” Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale, pp. 164–169, 2021.
E. Beghi et al., “The European Academy of Neurology COVID-19 registry (ENERGY): an international instrument for surveillance of neurological complications in patients with COVID-19,” Eur J Neurol, vol. 28, no. 10, 2021, doi: 10.1111/ene.14652.
S. Dewanjee, J. Vallamkondu, R. S. Kalra, N. Puvvada, R. Kandimalla, and P. H. Reddy, “Emerging COVID-19 Neurological Manifestations: Present Outlook and Potential Neurological Challenges in COVID-19 Pandemic,” 2021. doi: 10.1007/s12035- 021-02450-6.
O. Grosu, G. Zolotco, and G. Corcea, “Subarachnoid hemorrhage associated with COVID-19 infection,” International Journal of Stroke, vol. 16, no. 2 SUPPL, p. 162, 2021, [Online]. Available: papers3://publication/uuid/4C588966-D49E-4B6C-A928-6BD0CECD2FBD
V. Popa, O. Grosu, A. Manvelov, and E. Cebotari, “Neurological complications in patients with COVID 19 infections:results of the ENERGY study in Republic of Moldova,” no. 1, p. 207, 2021.
O. Grosu, V. Popa, A. Manvelov, and E. Cebotari, “STROKE AS THE MAIN PRESENTATION IN THE MOLDOVAN COHORT OF PATIENTS WITH COVID AND NEUROLOGICAL MANIFESTATION,” International Journal of Stroke, vol. 16, no. 2, p. 849, 2021.
V. Popa et al., “Preliminary results of the ENERGY study ( Ean NEuro-covid ReGistrY ) in the Republic of Moldova,” vol. 64, no. September, p. 2021, 2021.
C. Cazacu et al., “Cerebral venous thrombosis after COVID-9 infection : case report,” Moldovan medical Journal, vol. 64, no. September, p. 2021, 2021.
S. Jarius, N. Bieber, J. Haas, and B. Wildemann, “MOG encephalomyelitis after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2): case report and comprehensive review of the literature,” J Neurol, 2022, doi: 10.1007/s00415-022-11194-9.
A. Chatterjee and A. Chakravarty, “Neurological Complications Following COVID-19 Vaccination,” Jan. 01, 2023, Springer. doi: 10.1007/s11910-022- 01247-x.
B. S. Srichawla, T. Fang, V. Kipkorir, and M. A. Garcia-Dominguez, “Reversible cerebral vasoconstriction syndrome and posterior reversible encephalopathy syndrome following vaccination: analysis of the VAERS database and systematic review,” Annals of Medicine & Surgery, vol. 86, no. 3, pp. 1251–1260, Mar. 2024, doi: 10.1097/ms9.0000000000001407.
M. A. Islam, C. Cavestro, S. S. Alam, S. Kundu, M. A. Kamal, and F. Reza, “Encephalitis in Patients with COVID-19: A Systematic Evidence-Based Analysis,” Aug. 01, 2022, MDPI. doi: 10.3390/cells11162575.
N. Gulati, S. Kapila, L. Bhalla Sehgal, V. Sehgal, and P. LNU, “Myelitis Following COVID-19 Illness,” Cureus, Aug. 2022, doi: 10.7759/cureus.28134.
M. Yu, S. Nie, Y. Qiao, and Y. Ma, “Guillain-Barre syndrome following COVID-19 vaccines: A review of literature,” 2023, Frontiers Media S.A. doi: 10.3389/fimmu.2023.1078197.
M. T. Abuawwad et al., “Guillain-Barré syndrome after COVID-19 vaccination: A systematic review and analysis of case reports,” Mar. 01, 2024, Elsevier B.V. doi: 10.1016/j.clineuro.2024.108183.
B. N. Harapan and H. J. Yoo, “Neurological symptoms, manifestations, and complications associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19),” 2021. doi: 10.1007/s00415-021-10406-y.
S. Zhao, S. Toniolo, A. Hampshire, and M. Husain, “Effects of COVID-19 on cognition and brain health,” Nov. 01, 2023, Elsevier Ltd. doi: 10.1016/j.tics.2023.08.008.
C. M. Marra, C. Jose, T. Rudroo, and L. Chamard - Witkowski, “OPEN ACCESS EDITED AND REVIEWED BY Editorial: The NeuroCOVID- syndrome: cognitive and psychological profiles, physiopathology, and impact on neurologically vulnerable populations,” 2024, doi: 10.1001/jamaneurol.
B. F. Guedes, “NeuroCOVID-19: a critical review,” May 01, 2022, Associacao Arquivos de Neuro - Psiquiatria. doi: 10.1590/0004-282X-ANP-2022-S136.
Downloads
Published
License
Copyright (c) 2025 Bulletin of the Academy of Sciences of Moldova. Medical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
